You are here

Coalition Promotes Drug-Pricing Transparency

Hospitals, insurers, and businesses prod drug-makers

The Campaign for Sustainable Rx Pricing, a coalition of hospitals, insurers, and businesses, has released a policy proposal that aims to increase drug-pricing transparency and promote competition. The coalition includes the Federation of American Hospitals, the American Hospital Association, the Blue Cross Blue Shield Association, Kaiser Permanente, and the AARP.

The proposal calls for the following reforms:

  • Releasing details of a drug’s unit price, the cost of treatment, and a projection on federal spending before FDA approval
  • Annually reporting increases in a drug’s list price
  • Disclosing the true research and development costs for drugs
  • Speeding FDA approval of generic drug applications, especially for lifesaving drugs
  • Reducing drug monopolies by incentivizing competition for additional market entrants
  • Strengthening post-marketing clinical trials and surveillance
  • Targeting exclusivity protections to the most-innovative products
  • Curbing misuse of the Risk Evaluation and Mitigation Strategies (REMS) system
  • Promoting the uptake of biosimilars
  • Increasing funding for public and private research on drug pricing and value
  • Requiring drug-makers to compare the cost and outcomes of new drugs with those of existing therapies
  • Expanding value-based pricing in public programs

Not surprisingly, the pharmaceutical sector opposes any changes. An official with the Pharmaceutical Research and Manufacturers of America told the Washington Post that the coalition was a way for insurance companies to deflect scrutiny of their own role in drug pricing.

Sources: Campaign for Sustainable Rx Pricing; April 2016; and FierceHealthFinance; April 25, 2016.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed